# WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

**Search Results -**

| Term | Documents |
|---|---|
| B7.DWPI,EPAB,JPAB,USPT,PGPB. | 8654 |
| B7S | 0 |
| METHOD.DWPI,EPAB,JPAB,USPT,PGPB. | 4848553 |
| METHODS.DWPI,EPAB,JPAB,USPT,PGPB. | 1002899 |
| INHIBIT$ | 0 |
| INHIBIT.DWPI,EPAB,JPAB,USPT,PGPB. | 265581 |
| INHIBITA.DWPI,EPAB,JPAB,USPT,PGPB. | 2 |
| INHIBITABILITIES.DWPI,EPAB,JPAB,USPT,PGPB. | 1 |
| INHIBITABILITY.DWPI,EPAB,JPAB,USPT,PGPB. | 62 |
| INHIBITABLE.DWPI,EPAB,JPAB,USPT,PGPB. | 660 |
| . . . . . | |
| BLOCK$(BLOCKS-DETAILS).USPT,PGPB,JPAB,EPAB,DWPI. | pickup term |
| ((B7) SAME (METHOD) SAME (INHIBIT$ OR SUPPRESS$ OR BLOCK$ OR PREVENT$ OR ADMINIST$) ).USPT,PGPB,JPAB,EPAB,DWPI. | 164 |

There are more results than shown above. Click here to view the entire set.

**Database:**
US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search: (B7) same (method) same (inhibit$ or suppress$ or block$ or prevent$ or adminis t$)

Clear

**Search History**

**Today's Date: 9/9/2001**

| DB Name | Query | Hit Count | Set Name |
|---|---|---|---|
| USPT,PGPB,JPAB,EPAB,DWPI | (B7) same (method) same (inhibit$ or suppress$ or block$ or prevent$ or administ$) | 164 | L5 |
| USPT,PGPB | (B7) same (method).clm. | 34 | L4 |
| USPT,PGPB | (B7).clm. | 243 | L3 |
| USPT,PGPB | linsley-peter$ and B7 | 19 | L2 |
| USPT,PGPB | linsley-peter$ | 38 | L1 |

# WEST

Generate Collection

**Search Results** - Record(s) 1 through 10 of 19 returned.

☐ 1. Document ID: US 6183734 B1

L2: Entry 1 of 19 File: USPT Feb 6, 2001

US-PAT-NO: 6183734
DOCUMENT-IDENTIFIER: US 6183734 B1

TITLE: Inhibition of tumor cell growth by administration of B7-transfected cells

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Chen; Lieping | Seattle | WA | N/A | N/A |
| Hellstrom; Ingegerd | Seattle | WA | N/A | N/A |
| Hellstrom; Karl Erik | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Linsley; Peter S. | Seattle | WA | N/A | N/A |

US-CL-CURRENT: 424/93.21; 424/277.1, 424/278.1, 424/93.7, 435/325

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 6132992 A

L2: Entry 2 of 19 File: USPT Oct 17, 2000

US-PAT-NO: 6132992
DOCUMENT-IDENTIFIER: US 6132992 A

TITLE: Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell

DATE-ISSUED: October 17, 2000

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Gilliland; Lisa K. | Seattle | WA | N/A | N/A |
| Hayden; Martha S. | San Diego | CA | N/A | N/A |
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Bajorath; Jurgen | Everett | WA | N/A | N/A |
| Fell; H. Perry | Redmond | WA | N/A | N/A |

US-CL-CURRENT: 435/69.7; 435/320.1, 435/326, 435/328, 530/387.3, 530/387.9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 3. Document ID: US 6090914 A

L2: Entry 3 of 19 File: USPT Jul 18, 2000

US-PAT-NO: 6090914
DOCUMENT-IDENTIFIER: US 6090914 A

TITLE: CTLA4/CD28Ig hybrid fusion proteins and uses thereof

DATE-ISSUED: July 18, 2000

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Bajorath; Jurgen | Lynnwood | WA | N/A | N/A |
| Peach; Robert | Edmonds | WA | N/A | N/A |
| Brady; William | Edmonds | WA | N/A | N/A |

US-CL-CURRENT: 530/350; 424/192.1, 435/69.7, 530/387.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 4. Document ID: US 5993800 A

L2: Entry 4 of 19 File: USPT Nov 30, 1999

US-PAT-NO: 5993800
DOCUMENT-IDENTIFIER: US 5993800 A

TITLE: Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Kay; Mark A. | Seattle | WA | N/A | N/A |
| Wilson; Christopher B. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey | Seattle | WA | N/A | N/A |
| Aruffo; Alejandro A. | Seattle | WA | N/A | N/A |
| Hollenbaugh; Diane L. | Seattle | WA | N/A | N/A |

US-CL-CURRENT: 424/93.21; 424/93.1, 435/320.1, 435/325, 435/69.1, 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 5. Document ID: US 5977318 A

L2: Entry 5 of 19 File: USPT Nov 2, 1999

US-PAT-NO: 5977318
DOCUMENT-IDENTIFIER: US 5977318 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Damle; Nitin K. | Hopewell | NJ | N/A | N/A |
| Brady; William | Bothell | WA | N/A | N/A |
| Kiener; Peter A. | Edmonds | WA | N/A | N/A |

US-CL-CURRENT: 530/388.1; 424/141.1, 424/143.1, 435/331, 435/334, 530/388.15, 530/388.73, 530/861, 530/866, 530/868

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 6. Document ID: US 5968510 A

L2: Entry 6 of 19 File: USPT Oct 19, 1999

US-PAT-NO: 5968510
DOCUMENT-IDENTIFIER: US 5968510 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Damle; Nitin K. | Hopewell | NJ | N/A | N/A |
| Brady; William | Bothell | WA | N/A | N/A |
| Kiener; Peter A. | Edmonds | WA | N/A | N/A |

US-CL-CURRENT: 424/141.1; 424/139.1, 424/143.1, 424/154.1, 424/809, 424/810, 514/12, 514/2, 530/388.1, 530/388.15, 530/388.22, 530/388.73

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 7. Document ID: US 5916560 A

L2: Entry 7 of 19 File: USPT Jun 29, 1999

US-PAT-NO: 5916560
DOCUMENT-IDENTIFIER: US 5916560 A

TITLE: Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith

DATE-ISSUED: June 29, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Larsen; Christian P. | Atlanta | GA | N/A | N/A |
| Aruffo; Alejandro A. | Edmonds | WA | N/A | N/A |
| Hollenbaugh; Diane L. | Seattle | WA | N/A | N/A |
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Pearson; Thomas C. | Atlanta | GA | N/A | N/A |

US-CL-CURRENT: 424/154.1; 424/130.1, 424/139.1, 424/143.1, 424/153.1, 424/173.1, 514/2, 514/8, 530/387.3, 530/388.73, 530/388.75

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

---

☐ 8. Document ID: US 5885796 A

L2: Entry 8 of 19 File: USPT Mar 23, 1999

US-PAT-NO: 5885796
DOCUMENT-IDENTIFIER: US 5885796 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Damle; Nitin K. | Hopewell | NJ | N/A | N/A |
| Brady; William | Bothell | WA | N/A | N/A |

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.1, 536/23.4, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

---

☐ 9. Document ID: US 5885579 A

L2: Entry 9 of 19 File: USPT Mar 23, 1999

US-PAT-NO: 5885579
DOCUMENT-IDENTIFIER: US 5885579 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Damle; Nitin K. | Hopewell | NJ | N/A | N/A |
| Brady; William | Bothell | WA | N/A | N/A |
| Kiener; Peter A. | Edmonds | WA | N/A | N/A |

US-CL-CURRENT: 424/192.1; 424/133.1, 424/141.1, 435/69.1, 435/69.7, 435/7.2, 514/12, 514/2, 530/350, 530/387.1, 530/866 , 530/868

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

---

☐ 10. Document ID: US 5851795 A

L2: Entry 10 of 19 File: USPT Dec 22, 1998

US-PAT-NO: 5851795
DOCUMENT-IDENTIFIER: US 5851795 A

TITLE: Soluble CTLA4 molecules and uses thereof

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Damle; Nitin K. | Hopewell | NJ | N/A | N/A |
| Brady; William | Bothell | WA | N/A | N/A |
| Kiener; Peter A. | Edmonds | WA | N/A | N/A |

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/69.7, 530/350, 530/367, 530/387.3, 536/23.1, 536/23.4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

---

Generate Collection

| Term | Documents |
|---|---|
| LINSLEY-PETER$ | 0 |
| LINSLEY-PETER.USPT,PGPB. | 7 |
| LINSLEY-PETER-S.USPT,PGPB. | 31 |
| B7.USPT,PGPB. | 7269 |
| B7S | 0 |
| (LINSLEY-PETER$ AND B7).USPT,PGPB. | 19 |

Display 10 Documents, starting with Document: 11

**Display Format:** CIT Change Format

# WEST

Generate Collection

**Search Results** - Record(s) 11 through 19 of 19 returned.

☐ 11. Document ID: US 5844095 A

L2: Entry 11 of 19 File: USPT Dec 1, 1998

US-PAT-NO: 5844095
DOCUMENT-IDENTIFIER: US 5844095 A

TITLE: CTLA4 Ig fusion proteins

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Damle; Nitin K. | Hopewell | NJ | N/A | N/A |
| Brady; William | Bothell | WA | N/A | N/A |

US-CL-CURRENT: 530/387.3; 424/134.1, 424/192.1, 435/69.7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 12. Document ID: US 5807734 A

L2: Entry 12 of 19 File: USPT Sep 15, 1998

US-PAT-NO: 5807734
DOCUMENT-IDENTIFIER: US 5807734 A

TITLE: Monoclonal antibodies and FV specific for CD2 antigen

DATE-ISSUED: September 15, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Diegel; Michael L. | Kent | WA | N/A | N/A |
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Gilliland; Lisa K. | Seattle | WA | N/A | N/A |
| Moran; Patricia A. | Seattle | WA | N/A | N/A |
| Zarling; Joyce M. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |

US-CL-CURRENT: 435/252.33; 424/134.1, 424/135.1, 424/192.1, 435/320.1, 435/70.21, 514/44, 530/387.3, 530/388.22, 536/23.53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 13. Document ID: US 5795572 A

L2: Entry 13 of 19 File: USPT Aug 18, 1998

US-PAT-NO: 5795572
DOCUMENT-IDENTIFIER: US 5795572 A

TITLE: Monoclonal antibodies and FV specific for CD2 antigen

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Diegel; Michael L. | Kent | WA | N/A | N/A |
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Gilliland; Lisa K. | Seattle | WA | N/A | N/A |
| Moran; Patricia A. | Seattle | WA | N/A | N/A |
| Zarling; Joyce M. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |

US-CL-CURRENT: 424/135.1; 424/133.1, 424/141.1, 424/143.1, 424/154.1, 424/156.1, 424/178.1, 530/387.3, 530/388.1, 530/388.22, 530/391.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 14. Document ID: US 5773253 A

L2: Entry 14 of 19 File: USPT Jun 30, 1998

US-PAT-NO: 5773253
DOCUMENT-IDENTIFIER: US 5773253 A

TITLE: MYPPPY variants of CTL A4 and uses thereof

DATE-ISSUED: June 30, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Peach; Robert | Edmonds | WA | N/A | N/A |

US-CL-CURRENT: 435/69.7; 435/252.3, 435/320.1, 435/358, 435/361, 435/362, 435/69.1, 530/350, 530/387.1, 530/387.3, 530/388.75, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 15. Document ID: US 5770197 A

L2: Entry 15 of 19 File: USPT Jun 23, 1998

US-PAT-NO: 5770197
DOCUMENT-IDENTIFIER: US 5770197 A

TITLE: Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Damle; Nitin K. | Renton | WA | N/A | N/A |
| Brady; William | Bothell | WA | N/A | N/A |
| Wallace; Philip M. | Seattle | WA | N/A | N/A |

US-CL-CURRENT: 424/134.1; 424/139.1, 424/144.1, 424/192.1, 424/810, 435/69.7, 530/350, 530/388.7, 530/868

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 16. Document ID: US 5637481 A

L2: Entry 16 of 19 File: USPT Jun 10, 1997

US-PAT-NO: 5637481
DOCUMENT-IDENTIFIER: US 5637481 A

TITLE: Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell

DATE-ISSUED: June 10, 1997

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Gilliland; Lisa K. | Seattle | WA | N/A | N/A |
| Hayden; Martha S. | San Diego | CA | N/A | N/A |
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Bajorath; Jurgen | Everett | WA | N/A | N/A |
| Fell; H. Perry | Redmond | WA | N/A | N/A |

US-CL-CURRENT: 435/69.6; 435/320.1, 435/325, 435/326, 435/328, 435/332, 435/365, 435/69.1, 435/69.7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 17. Document ID: US 5580756 A

L2: Entry 17 of 19 File: USPT Dec 3, 1996

US-PAT-NO: 5580756
DOCUMENT-IDENTIFIER: US 5580756 A

TITLE: B7IG fusion protein

DATE-ISSUED: December 3, 1996

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Damle; Nitin K. | Renton | WA | N/A | N/A |
| Brady; William | Bothell | WA | N/A | N/A |

US-CL-CURRENT: 435/69.7; 435/91.1, 530/350, 530/387.1, 530/387.3, 530/395, 536/23.4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc | Image

---

☐ 18. Document ID: US 5521288 A

L2: Entry 18 of 19 File: USPT May 28, 1996

US-PAT-NO: 5521288
DOCUMENT-IDENTIFIER: US 5521288 A

TITLE: CD28IG fusion protein

DATE-ISSUED: May 28, 1996

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Damle; Nitin K. | Renton | WA | N/A | N/A |
| Brady; William | Bothell | WA | N/A | N/A |

US-CL-CURRENT: 530/387.3; 435/252.3, 435/252.33, 435/320.1, 435/69.1, 435/69.7, 435/7.2, 435/7.92, 435/91.1, 530/300, 530/350, 530/387.1, 530/395, 530/409, 530/866, 530/867, 530/868, 536/23.1, 536/23.4, 536/23.53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc | Image

---

☐ 19. Document ID: US 5434131 A

L2: Entry 19 of 19 File: USPT Jul 18, 1995

US-PAT-NO: 5434131
DOCUMENT-IDENTIFIER: US 5434131 A

TITLE: Chimeric CTLA4 receptor and methods for its use

DATE-ISSUED: July 18, 1995

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Linsley; Peter S. | Seattle | WA | N/A | N/A |
| Ledbetter; Jeffrey A. | Seattle | WA | N/A | N/A |
| Damle; Nitin K. | Renton | WA | N/A | N/A |
| Brady; William | Bothell | WA | N/A | N/A |

US-CL-CURRENT: 514/2; 424/133.1, 514/12, 530/350, 530/866, 530/868

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

Generate Collection

| Term | Documents |
|---|---|
| LINSLEY-PETER$ | 0 |
| LINSLEY-PETER.USPT,PGPB. | 7 |
| LINSLEY-PETER-S.USPT,PGPB. | 31 |
| B7.USPT,PGPB. | 7269 |
| B7S | 0 |
| (LINSLEY-PETER$ AND B7).USPT,PGPB. | 19 |

Display 10 Documents, starting with Document: 19

**Display Format:** CIT Change Format

2/7/23 (Item 23 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)


11848686 BIOSIS NO.: 199900094795
Targeting of A **B7**-1 (CD80) immunoglobulin G1 (IgG) **fusion** **protein** to acute myeloid leukemia (AML) blasts increases their costimulatory activity for autologous remission T cells.
AUTHOR: Willinger T; Thiel E; Notter M
AUTHOR ADDRESS: Dep. Hematol. Oncol., Lab. Applied Cell. Mol. Immunol., Universitaetsklin. Benjamin Franklin, FU Ber**Germany
JOURNAL: Annals of Hematology 77 (SUPPL. 2):pS112 1998
CONFERENCE/MEETING: Annual Congress of the German and Austrian Societies of Hematology and Oncology Frankfurt, Germany October 25-28, 1998
SPONSOR: Austrian Society of Hematology and Oncology
ISSN: 0939-5555
RECORD TYPE: Citation

2/7/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)


11876379 BIOSIS NO.: 199900122488
Systemic treatment with **soluble B7**-IgG fusion proteins significantly prolongs the survival of leukemic mice.
AUTHOR: Dunussi-Joannopoulos K; Runyon K; Sturmhoefel K; Schaub R G; Leonard J P
AUTHOR ADDRESS: Genet. Inst. Inc., Andover, MA**USA
JOURNAL: Blood 92 (10 SUPPL. 1 PART 1-2):p617A Nov. 15, 1998
CONFERENCE/MEETING: 40th Annual Meeting of the American Society of Hematology Miami Beach, Florida, USA December 4-8, 1998
SPONSOR: The American Society of Heamatology
ISSN: 0006-4971
RECORD TYPE: Citation

2/7/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)


12028015 BIOSIS NO.: 199900308534
Induction of therapeutic T-cell immunity by **tumor** targeting with **soluble** recombinant **B7**-immunoglobulin costimulatory molecules.
AUTHOR: Moro Monica; Gasparri Anna Maria; Pagano Stefano; Bellone Matteo; Tornaghi Paola; Veglia Fabrizio; Corti Angelo; Casorati Giulia; Dellabona Paolo(a)
AUTHOR ADDRESS: (a)Unita d'Immunochimica, DIBIT, Istituto Scientifico San Raffaele, Via Olgettina 58, Milan, 20132**Italy
JOURNAL: Cancer Research 59 (11):p2650-2656 June 1, 1999
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: **Tumor** targeting with immunomodulatory molecules is an attractive strategy to enhance the host's antitumor response. Expression of CD80 (B7-1) and CD86 (B7-2) costimulatory molecules in **tumor** cells has proven to be an efficient way to enhance their immunogenicity. Here, we studied the effects of **tumor** targeting with biotinylated recombinant **soluble** **B7**-1- and **B7**-2 immunoglobulin G molecules (bio-**B7**-IgG) using a pretargeting approach based on the sequential use of a biotinylated antitumor monoclonal antibody and avidin. Mouse RMA T-lymphoma cells bearing either bio-B7-1-IgG or bio-B7-2-IgG on their surface prime in vitro naive CD8+ CTLs, which are highly effective in adoptive immunotherapy, and induce therapeutic immunity when injected in **tumor**-bearing animals. In vivo targeting of established RMA **tumors** with bio-B7-IgG either cures **tumor** -bearing mice or significantly prolongs their survival. The antitumor response induced by targeted bio-B7-IgG depends on both CD4+ and CD8+ T cells. Moreover, **tumor** targeting with bio-B7-IgG in vivo is critical for both expansion in lymphoid organs and mobilization into the **tumor** of **tumor**-specific CD8+ CTLs. When targeting is performed on poorly immunogenic TS/A mammary adenocarcinoma, only bio-B7-1-IgG primes naive CTLs in vitro and cures or significantly prolongs the survival of **tumor**-bearing mice in vivo, confirming that the two costimulatory molecules are not redundant with this **tumor**. Altogether, these data suggest that **tumor** avidination and targeting with **soluble** bio-**B7**-IgG may represent a

```
s

Set     Items   Description
S1        138   (B7?)(20N)(SOLUBLE OR FUSION(W)PROTEIN) AND (TUMOR? OR TUM-
            OUR? OR CANCER? OR NEOPLAS?)
S2         75   RD S1 (unique items)
? s (B7?)(20n)(soluble or fusion(w)protein) and (autoimmun? or vivo or
transplant? or graft?)

Processing
          18476  B7?
         343737  SOLUBLE
         328213  FUSION
        3893136  PROTEIN
          43418  FUSION(W)PROTEIN
            648  B7?(20N)(SOLUBLE OR FUSION(W)PROTEIN)
         176215  AUTOIMMUN?
         942633  VIVO
        1267038  TRANSPLANT?
         456618  GRAFT?
      S3     382  (B7?)(20N)(SOLUBLE OR FUSION(W)PROTEIN) AND (AUTOIMMUN?
                  OR VIVO OR TRANSPLANT? OR GRAFT?)
? s s3 and review?

             382  S3
         2984937  REVIEW?
      S4      13  S3 AND REVIEW?
? rd s4

...completed examining records
      S5       7  RD S4 (unique items)
? t s5/7/all


 5/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09952450   BIOSIS NO.: 199598407368
Steroids as regulators of the mammalian immune response.
AUTHOR: Daynes Raymond A(a); Araneo Barbara A; Hennebold Jon; Enioutina
  Elena; Mu Hong Hua
AUTHOR ADDRESS: (a)Dep. Pathol., Univ. Utah Sch. Med., Salt Lake City, UT
  84132**USA
JOURNAL: Journal of Investigative Dermatology  105 (1 SUPPL.):p14S-19S 1995
ISSN: 0022-202X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The mammalian immune system is multicellular in composition, and
  its proper function requires careful control over complex developmental
  pathways and many distinct types of effector responses. Numerous
  overlapping mechanisms of intercellular communication are needed to
  accomplish the tasks of proper regulation of the diverse cell types that
  constitute this essential protective system. One mechanism occurs by
  direct cell-to-cell contact through the interaction of
  membrane-associated molecules. Examples of this type of communication
  include the interaction that takes place between the antigen-specific
```

T-cell receptor and the foreign peptides that are bound to major histocompatibility complex molecules, as well as costimulatory molecule interactions with their specific ligands expressed on antigen-presenting cells (e.g., CD28 and **B7**-1 or **B7**-2). A second mechanism occurs through the production, secretion, and activities of **soluble** mediators, collectively known as the cytokines. The cytokines are represented by a large and diverse group of molecules that are produced by a wide variety of cell types. Unique species of cytokines bind to specific membrane-associated receptors on target cells, inducing the activation of particular signal-transduction pathways. These processes subsequently lead to the diversity of cytokine-linked changes in cellular physiology. Some of the cytokines exert their influences in **vivo** via endocrine routes, although it is far more common for intercellular communication via cytokines to occur microenvironmentally via paracrine or autocrine pathways. The object of this **review** is to provide evidence supporting the concept that one mechanism for upstream regulation of cytokine production by immunocompetent cell types is controlled by the regulatory activities of various steroid hormones. Strain variation in susceptibility to infectious agents, the condition of immunosenescence, and the processes that control the development of common mucosal immunity are used as examples of immune mechanisms that may be under steroid hormone control.

5/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)


09783333 BIOSIS NO.: 199598238251
Immunotherapy of multiple myeloma.
AUTHOR: Huang Yi-Wu; Vitetta Ellen S(a)
AUTHOR ADDRESS: (a)Univ. Texas Southwestern Med. Cent., Cancer Immunobiol. Cent., 6000 Harry Hines Blvd., NB9 210, **USA
JOURNAL: Stem Cells (Dayton) 13 (2):p123-134 1995
ISSN: 1066-5099
DOCUMENT TYPE: Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: In 1994, an estimated 12,700 new cases of multiple myeloma (MM) will be diagnosed in the USA and 9,800 patients will die from this disease. At present, a cure for MM has not been achieved with any chemotherapeutic regimen. Therefore, it is important to develop novel therapeutic approaches to treat this fatal disease. This **review** focuses on new concepts in the immunotherapy of MM. Thus far, interferons and anti-human interleukin (IL)-6 monoclonal antibodies (MAbs) have been used to treat patients with this disease. Bone marrow **transplantation** using autologous marrow purged with MAbs and complement, with anti-myeloma immunotoxins (ITs), or MAb-magnetic bead conjugates has been reported. Adoptive cellular therapy, in **vivo** with anti-CD3 and IL-2, as well as **transplantation** of purified autologous CD34+ peripheral blood stem cells, is now being evaluated in clinical trials. Antihuman IL-6 receptor (IL-6R) and anti-CD54 (ICAM-1) MAbs have shown promising results in the therapy of human myeloma cell lines in SCID mice, while an IL-6 antagonist protein, anti-gp130 MAbs, recombinant **soluble** gp130, anti-**B7**, antiHLA-DR, and recombinant **soluble** CD16 also inhibit the growth of mveloma cell lines in vitro. These experimental therapeutic modalities hold promise for use in humans and may also provide further insights into the pathogenesis of MM.

5/7/3 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

06417456 EMBASE No: 1996080901
Costimulation and its role in organ **transplantation**
Bluestone J.A.
Ben May Institute, University of Chicago, 5841 South Maryland Avenue,Chicago, IL-60637-1470 United States
Clinical Transplantation ( CLIN. TRANSPLANT. ) (Denmark) 1996, 10/1 II (104-109)
CODEN: CLTRE ISSN: 0902-0063
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Antigen-specific T-cell activation depends initially on the interaction of the T-cell receptor with peptide/major histocompatibility complex (MHC). in addition, a costimulatory signal, mediated by distinct cell surface accessory molecules such as CD28, is required for complete T-cell activation. One essential element of the CD28 costimulatory system that makes it an attractive target for immunotherapy is the selective effect of CD28 antagonists on activated T cells. Only cells encountering antigen presenting cells (APCs) without the appropriate CD28 ligand will be rendered functionally inactive as desired for any next-generation immunosuppressive drug. This brief **review** will focus on the role of CD28/B7 interactions in regulating organ **graft** rejection. In vitro and in **vivo** studies will describe the use of a **soluble fusion protein** antagonist of CD28/**B7** (CTLA-4Ig), anti-**B7** MAbs, and genetically altered CD28 'knockout' mice to study immune responses. The studies suggest that: 1) CTLA-4Ig induces long term, antigen specific unresponsiveness in **vivo**; 2) two distinct ligands for CD28, B7-1 and B7-2, are differentially regulated during immune responses; and 3) both B7-1 and B7-2 costimulatory molecules are active, in **vivo**, although B7-2 plays a clearly dominant role in murine allograft rejection.

5/7/4 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE


06361238 EMBASE No: 1996025020
B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis
Perrin P.J.; Scott D.; June C.H.; Racke M.K.
Immune Cell Biology Program, Naval Medical Research Institute, Mail Stop 06,Bethesda, MD 20889-5607 United States
Immunologic Research ( IMMUNOL. RES. ) (Switzerland) 1995, 14/3 (189-199)
CODEN: IMRSE ISSN: 0257-277X
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

T-cell activation requires signalling provided by ligation of the T-cell receptor for antigen (TCR) and a second antigen (Ag) nonspecific signal, known as costimulation. The B7 receptors, CD80 (B7-1) and CD86 (B7-2), on the Ag-presenting cell (APC), interact with T-cell CD28 or CTLA-4 to deliver a costimulatory signal, which is particularly important for Th1 activation. Experimental allergic encephalomyelitis (EAE) is an **autoimmune** disorder, induced by Th1 cells directed against myelin antigens that provides an in **vivo** model for studying the role of **B7**-mediated costimulation in the induction of a pathological immune response. Using a **soluble fusion protein** ligand for the **B7** receptors, as well as specific monoclonal antibodies specific for either CD80 or CD86, it has been demonstrated that B7 costimulation plays a prominent role in determining clinical disease outcome in EAE. Here we **review** recent data indicating that a paradoxical exacerbation of disease as well as the expected amelioration of disease can occur with costimulatory receptor blockade.

5/7/5 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE


06234052 EMBASE No: 1995252008
Blocking CD28/**B7** with **soluble** competitors: Immunological phenotype of mCTLA4-Hgamma1 transgenic mice
Lane P.
Basel Institute for Immunology, Grenzacherstrasse 487,Basel CH-4005 Switzerland
Research in Immunology ( RES. IMMUNOL. ) (France) 1995, 146/3 (176-179)
CODEN: RIMME ISSN: 0923-2494
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH

5/7/6 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE


06008923 EMBASE No: 1995037578
Immunomodulation of **transplant** rejection using monoclonal antibodies and soluble receptors
Alegre M.-L.; Lenschow D.J.; Bluestone J.A.
Department of Pathology, University of Chicago,Chicago, IL 60637 United States
Digestive Diseases and Sciences ( DIG. DIS. SCI. ) (United States) 1995, 40/1 (58-64)
CODEN: DDSCD ISSN: 0163-2116
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

The main objective of our studies has been to optimize the effects of monoclonal antibodies (MAbs) and other immunosuppressive reagents to enhance organ **graft** survival. One such agent is OKT3, a MAb that is directed against the CD3 component of the human T-cell receptor (TCR) complex. Treatment of a rejection episode with OKT3 results in a rapid and efficient clearing of circulating T cells and reversal of most rejection episodes. Its wider use in **transplantation** and in the treatment of immune-mediated disease is limited by adverse reactions that follow the initial dose, the production of neutralizing Abs, and the transient nature of the immunosuppression. We have engineered CDR-**grafted** 'humanized' anti-CD3 MAbs that lack Fc-receptor binding activity through mutagenesis of amino acids in the Fc portion of the MAb. This results in an immunosuppressive anti-CD3 MAb that is less antigenic and one that does not induce the first-dose side effects. In addition, we have pursued a goal of developing a therapy that will induce donor-specific tolerance while maintaining overall recipient immune competency. Because antigen-specific T-cell activation depends not only on TCR-ligand interaction, but also on additional costimulatory signals mediated by accessory molecules such as CD28, blocking the binding of CD28 on T cells to its-ligand **B7**, during TCR engagement, might modulate **transplantation** responses. Using a **soluble fusion protein** of human CTLA4, CTLA4-Ig, that binds **B7** with high affinity, inhibition of human pancreatic islet rejection that occurs, at least in part, by affecting T-cell recognition of human B7sup + antigen-presenting cells has been demonstrated. In addition, CTLA4-Ig induces long-term, donor-specific unresponsiveness.

5/7/7 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)


131003885 CA: 131(1)3885b JOURNAL
Immunomodulation of the CD28-B7 system: effects of inhibition of

co-stimulatory signals provided by CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis

AUTHOR(S): Nishikawa, K.; Matsuo, S.
LOCATION: Division of Nephrology, The Third Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan, 466-8550

JOURNAL: Nephrol., Dial., Transplant. DATE: 1999 VOLUME: 14 NUMBER: Suppl. 1 PAGES: 19-21 CODEN: NDTREA ISSN: 0931-0509 LANGUAGE: English
PUBLISHER: Oxford University Press
SECTION:
CA215000 Immunochemistry
IDENTIFIERS: review CD28 B7 signaling autoimmune glomerulonephritis, CTLA 4Ig autoimmune glomerulonephritis review
DESCRIPTORS:
Kidney,disease...
autoimmune glomerulonephritis; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis
Fusion proteins(chimeric proteins)...
CTLA-4Ig, fusion protein with CTLA-4 antigen and IgG; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis and
CTLA-4(antigen)...
CTLA-4Ig, fusion protein with IgG and; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis and response to
CD28(antigen)... CD80(antigen)... Signal transduction,biological...
effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis
Immunoglobulins...
G, CTLA-4Ig, fusion protein with CTLA-4 antigen 0; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis and res
Basement membrane...
glomerular; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis
Immune complexes...
IgG-contg.; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis and inhibition of deposition of
Immunoglobulins...
to .alpha.3 chain type IV collagen; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis
Collagens,biological studies...
type IV, .alpha.3 chain; effects of inhibition of co-stimulatory signals in CD28-B7 interaction on rat autoimmune anti-glomerular basement membrane glomerulonephritis and inhibition of

| Set | Items | Description |
|---|---|---|
| S1 | 138 | (B7?)(20N)(SOLUBLE OR FUSION(W)PROTEIN) AND (TUMOR? OR TUMOUR? OR CANCER? OR NEOPLAS?) |
| S2 | 75 | RD S1 (unique items) |
| S3 | 382 | (B7?)(20N)(SOLUBLE OR FUSION(W)PROTEIN) AND (AUTOIMMUN? OR VIVO OR TRANSPLANT? OR GRAFT?) |
| S4 | 13 | S3 AND REVIEW? |
| S5 | 7 | RD S4 (unique items) |

# WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

**Search Results -**

| Term | Documents |
|---|---|
| B7.DWPI,EPAB,JPAB,USPT,PGPB. | 8654 |
| B7S | 0 |
| METHOD.DWPI,EPAB,JPAB,USPT,PGPB. | 4848553 |
| METHODS.DWPI,EPAB,JPAB,USPT,PGPB. | 1002899 |
| INHIBIT$ | 0 |
| INHIBIT.DWPI,EPAB,JPAB,USPT,PGPB. | 265581 |
| INHIBITA.DWPI,EPAB,JPAB,USPT,PGPB. | 2 |
| INHIBITABILITIES.DWPI,EPAB,JPAB,USPT,PGPB. | 1 |
| INHIBITABILITY.DWPI,EPAB,JPAB,USPT,PGPB. | 62 |
| INHIBITABLE.DWPI,EPAB,JPAB,USPT,PGPB. | 660 |
| . . . . . | |
| BLOCK$(BLOCKS-DETAILS).USPT,PGPB,JPAB,EPAB,DWPI. | pickup term |
| ((B7) SAME (METHOD) SAME (INHIBIT$ OR SUPPRESS$ OR BLOCK$ OR PREVENT$ OR ADMINIST$) AND (CANCER OR NEOPLASIA OR TUMOR$ OR TUMOUR$) ).USPT,PGPB,JPAB,EPAB,DWPI. | 107 |

There are more results than shown above. Click here to view the entire set.

**Database:** US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Refine Search: (B7) same (method) same (inhibit$ or suppress$ or block$ or prevent$ or administ$) and (cancer or neoplasia or

Clear

**Search History**

**Today's Date: 9/9/2001**

| DB Name | Query | Hit Count | Set Name |
|---|---|---|---|
| USPT,PGPB,JPAB,EPAB,DWPI | (B7) same (method) same (inhibit$ or suppress$ or block$ or prevent$ or administ$) and (cancer or neoplasia or tumor$ or tumour$) | 107 | L6 |
| USPT,PGPB,JPAB,EPAB,DWPI | (B7) same (method) same (inhibit$ or suppress$ or block$ or prevent$ or administ$) | 164 | L5 |
| USPT,PGPB | (B7) same (method).clm. | 34 | L4 |
| USPT,PGPB | (B7).clm. | 243 | L3 |
| USPT,PGPB | linsley-peter$ and B7 | 19 | L2 |
| USPT,PGPB | linsley-peter$ | 38 | L1 |

2/7/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)


12203408 BIOSIS NO.: 199900498257
Immune response enhancement by in vivo administration of **B7**.2Ig, a **soluble** costimulatory protein.
AUTHOR: Swiniarski Holly; Sturmhoefel Knut; Lee Kwang; Gray Gary S; Thomas Jenifer L; Wolf Stanley F; Dorner Andrew J; O'Toole Margot(a)
AUTHOR ADDRESS: (a)Genetics Institute, One Burtt Road, Andover, MA, 01810** USA
JOURNAL: Clinical Immunology (Orlando) 92 (3):p235-245 Sept., 1999
ISSN: 1521-6616
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: The identification of both class I- and class II-restricted **tumor**-associated peptides recognized by T cells has led to the test of these peptides as immunogens in experimental immunotherapy for **cancer** patients. However, optimal T cell activation requires signaling both through the T cell receptor for antigen and through costimulatory pathways. B7.1 and B7.2 are powerful costimulatory molecules expressed on the surface of antigen-presenting cells. Using a mouse model, we have sought to optimize costimulatory signals during antipeptide responses by administering a **soluble** form of **B7**.2 at the time of peptide immunization. Administration of **B7**.2Ig **fusion protein** significantly enhanced T helper cell and CTL responses. These findings suggest that **soluble** forms of human **B7**.2 protein may provide a straightforward and practical method of supplying optimal costimulation during clinical immunotherapy.